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Abstract: 
Rheumatoid arthritis (RA) is a chronic systemic inflammatory disease of unidentified aetiology, chiefly affecting the synovial membranes of joints, cartilage, bone, 
bursa and tendon sheath. Osteoarthritis (OA) is a degenerative disorder and encompass different sets of pathogenic pathways than RA; however, it shows a medley 
of clinical manifestations or symptoms resembling RA. Hence, we intend to identify more disease specific biomarkers through the meta-analysis of microarray 
datasets that can be crucial in the differential diagnosis, disease specific treatment as well as management of both RA and OA in a typical clinical setting. 
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Background: 
Autoimmune diseases arise from an overactive immune response wherein the 
immune system mistakes some parts of the body as pathogen and attacks its 
own cells. Systemic autoimmune disease such as Rheumatoid arthritis (RA) 
affects the synovial membranes of multiple joints, cartilage and bone as well as 
bursa and tendon sheaths [1]. Osteoarthritis (OA), on the other hand, is a 
degenerative disorder of the joints showing similar symptoms such as RA. 
Although both the diseases share similar symptoms, it has been proposed that 
RA follows an inflammatory pathway of pathogenesis, thus, differentiating it 
from OA. Diagnosis and assessment of RA and OA depend to a great extent on 
the symptoms, joint damage and physical function which are semi quantitative 
methods of diagnosis. Till date no definite cure has been proposed for RA, 
management of this disease depends upon early detection and aggressive 
treatment. Several studies have been undertaken to identify and validate 
biomarkers that would help in early detection and better monitoring of these 
diseases. Studies have revealed  biomarkers for RA including genetic 
association of RA with HLR-DR family (DR4, DR1, DR6 AND DR10) alleles 
within class II MHC region within chromosome 6 [2, 3], increased level of pro 
inflammatory cytokines (TNF-α,IL-1β and IL-6) [1, 4], elevated level of 
SPHK1 in synovium membrane of RA [5-7]. Similarly, investigation of gene 
signatures of OA provided significant results including presence of MMPs, 
collagenase -1, MMP-3, IL-6 and TNF-α in the synovial fluid of arthritis 
patients  [8, 9, 10]. Despite these findings and the on-going intensive 
investigation of the genetic pattern of these diseases, we are yet to reach an 
integrated outlook. Microarrays [11] have been used to study the gene 
expression patterns associated with various diseases models in both basic and 
translational research in the past decade [12-24]. It helps to probe into the key 
biomarkers implicated in the pathogenesis and may provide clues for the 
treatment or management of human diseases. Thus, for our investigation, we 
applied the bioinformatics approach on publicly available microarray datasets 
of RA and OA in an attempt to identify key biomarkers specific to each of 
these diseases.  
 
Methodology: 
For our analysis, all the datasets used were Affymetrix CEL files. Using the 
Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/geo/) and search 
criteria based upon our aim of the experiment, three datasets were selected out 
of the available 77 datasets related to RA and OA. These datasets were 
obtained from experiments which were performed with cell lines or tissue, 
using different technology and platforms (Table 1 see Supplementary 
material). Affymetrix CEL files were uploaded into GeneSpring GX 10.0 for 
statistical analysis. Normalization was performed using RMA and baseline 
transformation algorithm. Quality check was performed to remove unreliable 
data if any from each of the datasets. Statistical analysis was performed to 
determine differentially expressed genes. In case of all the datasets the fold 
change for every condition was calculated keeping Normal Donor expressions 
as the control condition. The cut off was set at 2.0 for all the datasets. The 
resulting fold change list was then subjected to statistical analysis. For all the 
datasets, the entity list selected was the one obtained after filtration by Fold 
Change (> = 2.0). The statistical test selected was one way ANOVA for data 
sets GSE1919 & GSE 12021, since there were more than two groups in each of 
these datasets and the cut off was adjusted at p< = 0.05. Student t-test was used BIOINFORMATION  open access 
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for GSE10500 (since there were only two groups to be compared). Multiple 
testing, Benjamini Hochberg FDR was used for data set GSE1919. Hierarchical 
clustering was run for each of the resulting statistically significant entity lists. 
Cluster on both entities and condition was selected for all the datasets and the 
distance metric selected for all the datasets was Euclidean.  
 
Results and Discussion: 
Cluster analysis of the selected datasets: 
Statistical analyses performed on the datasets showed encouraging results 
(Table 2 see Supplementary material) and hence, hierarchical clustering 
(HCL) was applied to each of the datasets to visualize the significant gene 
clusters and their specific pattern of expression in normal as well as test 
samples. As expected, the HCL (Figure 1) uncovered the differential gene 
expression patterns for each of the dataset analyzed when compared with the 
corresponding control groups. The differential expression of genes in normal 
control against RA patients showed regions where there was down regulation 
of genes in the normal control whereas up regulation at that region can be 
observed in RA genes, indicating the difference in gene expression patterns in 
diseased and normal states. Similar observations can be made for each of the 
other datasets. 
 
 
Figure 1: Dendrograms generated by hierarchical clustering algorithm using 
GeneSpring GX10.0 for each dataset (GSE10500, GSE1919, GSE12021) 
showing the gene signatures of RA and OA compared with NC (NC-Normal 
Control, RA- Rheumatoid Arthritis, OA- Osteoarthritis). 
 
Gene expression analysis in RA: 
Data set GSE10500 was used in understanding the pathogenesis of RA. Pro 
inflammatory genes such as TNF, NFAT, cJUN, IL15 showed increased 
expression in diseased state (Table 3 see Supplementary material). On the 
other hand, anti-inflammatory cytokines such as Interleukin 10 (IL 10) and its 
receptor (IL10RB) showed decreased expression. Additionally, there was 
increased expression of chemokines such as IL8 and CCL7. Up regulation of 
genes related to signal transduction such as GEM, NR4A2 were also reported. 
Genes regulating proteases were also found to be up regulated (MMP1, 
MMP3). Additionally, one of the interesting observations was the expression of 
transcription factor ATF4 associated with Endoplasmic reticulum (ER) stress 
pathway and VEGF associated with angiogenesis. 
 
Gene expression profile of RA and OA: 
The datasets GSE1919& GSE12021 were used to distinguish between OA and 
RA. These datasets showed interesting results (Table 4 see Supplementary 
material). The expression of genes related to pro inflammatory genes were up 
regulated in case of both OA and RA indicating inflammation as a condition in 
both the diseased states. Chemokines (IL8, CXCL12, CCL5, CCR5) that aid in 
mounting an increased immune response were also found to be expressed. 
Other Immunoregulatory genes such as FCGR1A, FCGR3A were found to be 
up regulated in both RA and OA. Additionally, certain genes involved in 
regulation of Phospholipase C (PLCG2) were seen to be up regulated in both 
OA and RA. Though activity of PLC in RA has been reported earlier, in case of 
OA, it was something unusual. Cytokines have been found to be playing a 
major role in RA. They promote autoimmunity by maintaining chronic 
inflammatory synovitis leading to the destruction of adjacent joint tissues(1). 
Cytokines have therefore, been found to combine the immune regulatory and 
tissue destructive events that lead to progression of RA.  In our metanalysis, we 
have found that there was an up regulation of genes coding for pro-
inflammatory cytokines IL-1β, TNF-α, IL-15 etc., (Table 3). IL-1β plays a key 
role in triggering the up-regulation of pro-inflammatory factors (Okusawa S 
et.al 2005).  
 
Role of T cells in RA: 
In all the datasets analysed, there was an up regulation of T-cell receptor alpha 
chain (TRAα) (Table 3 & 4) indicating that T-cells play pivotal role in the 
pathogenesis of RA. Another indication of involvement of T cells is the up 
regulation of IL-15 which is one of the key growth factor for the synovial T-
cells  [25]. Some of the studies have shown that IL-15 exhibited pro 
inflammatory activity in vitro [25] as well as in the animal models of arthritis 
[26] suggesting that IL15 plays an important role in RA. Interleukin 8 (IL8) a 
chemokine, showed increased activity in RA samples in two out of three 
datasets (GSE10500, GSE1919). It can be seen IL8 might possibly play an 
important role in the pathogenesis of RA. It helps in up regulating the 
expression of genes involved in angiogenesis (VEGF), as well as tumor 
invasions (MMP2 and MMP9). IL8 triggers inflammation in cells like 
neutrophils leading to chemotaxis, respiratory burst, granule release, increased 
cell adhesion and mobilization of Ca2+ in the cell, thus, helping initiation of 
expression of Ca2+ dependent transcription factors like NFAT. It thus, 
becomes evident that IL8 plays an important role in the pathogenesis of RA 
patients.  Our results on RA datasets have shown the differential regulation of 
most of these genes already found in the literature and strongly supports the 
involvement of proinflammatory mediators released from the auto-reactive 
immune cells in the pathogenesis of RA. 
 
Role of B cells in RA: 
The potential involvement of B cells in the development of RA is also 
indicated by the up regulation of some of the specific genes (CXCL13, CCL21, 
MMP1, MMP3) (Table 3 & 4). Mature dendritic cells in synovial membranes 
ectopic germinal centres produce increased level of B-cell survival factor 
(tumor necrosis superfamily member TNFSF13) [27, 28]. Increased expression 
of Tumor Necrosis Factor Superfamily (TNFSF) members (Table 4) indicates 
the B cell survival during the pathogenesis of RA. The lymphocyte infiltrate in 
the RA synovium has various patterns of structural organizations. A study has 
shown that that the  formation of ectopic germinal centres aids in the improper 
regulation of self-reactive B cells, due to local affinity maturation and receptor 
editing  [28]. In addition, the cytokines and chemokines contribute to this 
lymphocyte organization. For example, the CXC-chemokine ligand 13 
(CXCL13) and CCL21 help the formation of synovial germinal centres [29]. In 
our results, although expression of CXCL13 was not observed, another 
chemokine family member, CXCL12 (Table 4) was found to be up regulated in 
RA samples. Moreover, the chemokine CCL5, MMP1and MMP3 were up 
regulated in patients with RA (Table 4) which are expressed by synovial 
fibroblasts and are shown to support the recruitment and activation of T cells 
[1]. Production of vascular endothelial growth factor (VEGF) was reported by 
samples from dataset GSE1919 & GSE10500 (Table 3 & 4). The potential 
function played by VEGF in pathogenesis of RA is angiogenesis. It has been 
reported that several pathological conditions including RA are characterized by 
excessive angiogenesis where vessels develop in an uncontrolled or 
disorganized manner [30]. Together, these data indicate a central role played by 
cytokines in integrating the inflammatory and destructive phases in RA. 
Certain genes such as GTP binding protein overexpressed in skeletal muscle, 
Nuclear receptor subfamily 4, group A, member 2 (GEM & NR4A2) belonging 
to the functional group of signal transduction showed up regulation in RA. 
During mast cell activation, many signaling molecules are engaged in diverse 
activities including generation of lipid derived pro inflammatory mediators and 
the production of cytokines and chemokines [31]. Hence, the up regulation of 
the above mentioned genes indicate an inflammatory state that is typical in 
patients with RA. Thus, it was observed that across all datasets, the samples 
from RA patients showed the differential expression of genes involved in the 
inflammatory response, which aids in the pathogenesis of the disease. 
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Association of RA with Atherosclerosis: 
An interesting finding from the analysis of the dataset GSE10500 was the 
increased expression of genes related to the pathogenesis of atherosclerosis 
such as IL8, MMP1, and TNFSF14. Our findings support several other 
recorded data that the above mentioned genes play a role in promoting 
inflammatory response in atherosclerosis [32]. It can be seen that pro 
inflammatory cytokine producing genes IL1 and IL8 have been increased 
across the datasets. Additionally, tissue factor (TF) and MMP3 are also up 
regulated indicating an inflammatory condition. This condition stimulates 
Smooth Muscle Cells (SMC) proliferation and initial migration towards the 
lesion ultimately forming the stable plaque which is large lipid core covered by 
a thick fibro-muscular cap with SMC and extra cellular matrix (EMC). Under 
conditions of chronic inflammation, this stable plaque transforms into a 
vulnerable plaque. This is aided by a cascade of events that ultimately lead to 
rupturing of the vulnerable plaques resulting in thrombosis and possible 
myocardial infarction. As can be seen, a condition of chronic inflammatory 
response, such as in case of RA, simply helps in initiation and deterioration of 
atherosclerosis. There is evidence that cardiovascular disease is the leading 
cause of mortality in patients with chronic inflammatory disease [33]. 
Additionally, it has been reported that RA patients have increased prevalence to 
subclinical atherosclerosis [34]. This observation suggests that patients with 
chronic inflammatory disorders, such as RA, are at an increased risk of 
cardiovascular disease due to shared pathogenic pathways.  
 
Association of ER pathway and RA: 
An important observation was up regulation of gene ATF4 (Table 4). This 
particular gene has previously been associated with Endoplasmic stress 
reticulum pathway [35].This suggests that there is a correlation between 
patients suffering from RA and the development of stress due to the disease. 
ER-initiated cell death pathways have been recognized for several diseases 
such as hypoxia, ischemia, heart disease, neurodegeneration and diabetes [36]. 
Although no data have been published on the involvement of stress pathway in 
RA, our finding suggests a possibility that the stress might also play a pivotal 
role in the aggravation of RA or vice versa. 
 
 
Figure 2: Representation of number of genes up regulated in RA and OA 
(GSE1919) using Venn diagram. Entity List 1 represents up regulated genes 
associated with OA. Entity List 2 represents up regulated genes associated with 
RA. Entity List 3 represents all the up regulated genes obtained after filtration 
by fold change (cut off >= 2.0).  
 
Role of PLCγ in OA: 
An interesting finding was the differential regulation of genes Phospholipase C 
gamma (PLCγ) (Table 4). PLCγ signaling has been previously associated with 
disorders related to cellular development and cell signaling. Although there 
have been reports of PLC in rheumatoid arthritis, no records have been 
published related to involvement of PLC in OA. Expression of PLCγ in patients 
with RA is expected as PLC γ is activated by TCR, BCR, the high affinity IgE 
receptor and IgG receptors. In RA, there is an increased expression of TCR and 
BCR, thus, aiding the activation of PLCγ. Previous studies have shown that RA 
can be associated with increased expression of PLCγ in synovial tissues [37]. 
Activation of PLCγ leads to hydrolysis of PIP2 which releases second 
messengers DAG and IP3, out of which, IP3 stimulates the release of stored 
Ca2+ from ER. This released Ca2+ aids in the activity of transcription factor 
NFAT. A study by the same group showed that PLCγ does not play any role in 
osteoarthritis in human [37]. However, from our results, PLCγ can be seen to 
be up regulated even in case of OA, suggesting a similar potential role played 
by it in the pathogenesis of RA. The number of genes up regulated in both RA 
and OA was more when compared to the genes uniquely expressed by each of 
them (Figure 2). This indicates that both RA and OA share the key pathway 
responsible for the pathogenesis to some extent. The differentially expressed 
genes in the pathogenesis of RA and OA from the dataset GSE1919 showed up 
regulation of genes linked to the proinflammatory pathways. In case of RA, this 
was very well expected. However, increased expression of these genes in OA 
was very interesting; since it is not an inflammatory disorder, but a 
degenerative disorder. However, it may be assumed that in case of OA, after 
the initial cartilage damage due to physical/mechanical stress, the infiltration of 
immune cells leading to the release of inflammatory effectors as a part of the 
innate immune response. This could explain the differential expression levels 
of these proinflammatory genes in OA. However, the observation of the fold 
change of the genes in RA and OA indicates that there is a much higher up 
regulation of the genes in RA than OA. 
 
Conclusion: 
This study is an attempt to identify potential biomarkers for RA and OA as well 
as to differentiate between the two disorders with respect to biomarkers. As it is 
observed from the results, the expression of cytokines plays an important role 
in the pathogenesis of these two debilitating diseases. Understanding the 
cytokine signaling cascade might aid in targeting these pathways during early 
stages of these diseases to induce tolerance. Apart from the pro inflammatory 
genes, other genes that help in mounting an increased immune response were 
also identified across all the datasets. Our study also identified some unique 
gene signatures such as ATF4 in RA (ER stress pathway), PLCγ signaling in 
OA, IL8 signaling in RA from our datasets. These pathways can be further 
investigated in detail for their roles in the disease prognosis to design 
personalized medicines or therapeutics based on the disease type and stage in 
individual patients. Moreover, this study highlights how inflammatory 
cardiovascular disease like Atherosclerosis and RA are co-related in terms of 
their pathogenic pathways. Hence, it can be concluded that patients with RA 
run a higher risk of atherosclerosis and therefore, should be screened regularly 
for cardiovascular disorders. 
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Supplementary material: 
 
Table 1: Characteristics of the analyzed microarray data sets 
Author  Accession no.  Platform  Sample Information 
Ivashkiv LB et.al 2008 
Unpublished 
GSE10500 GPL8300 
[HG_U95Av2] 
Synovial macrophages Samples 8 
4-RA donor, 4-ND 
Ungethuem U et.al 2004 
Unpublished 
GSE1919  GPL91 [HG_U95A]  Synovial fibroblasts Samples-15 
5-RA, 5-OA, 5-ND 
Huber R et.al 2008  GSE12021  GPL96 [HG_U133A] 
GPL97 [HG_U133B] 
Synovial membrane 
Samples-15 
5-RA, 5-OA, 5-ND 
 
Table 2: Summary of parameters applied on the microarray data sets for the meta-analysis  
Dataset  Entities Selected  Statistical Test  Fold Change cut off  p-Value cut off 
GSE12021  586/22283 ANOVA >=  2.0  <=0.05 
GSE1919 941/1318  ANOVA  >=  2.0  <=0.05 
GSE10500 723/940  t-Test  >=  2.0  <=0.05 
 
 
Table 3: Differentially expressed genes observed in RA datasets, which have already been reported in literature 
Enterez Gene Name  Gene Symbol  Function  Fold Change 
Interleukin 1 receptor accessory protein  IL-1RAP  Cytokine  3.225 
Interleukin 8  IL-8  Chemokine  4.851 
Tumor Necrosis Factor  TNF  Cytokine  5.231 
Matrix metalloproteinase 1  MMP-1  Enzyme  4.379 
Nuclear factor  of activated T cells  NFAT  Transcription factor  2.333 
JUN oncogene  cJUN  Transcription regulator  3.343 
T-cell receptor alpha locus  TRA@  Receptor  2.391 
Activating Transcription factor  ATF4  Transcription factor  3.512 
Chemokine (C-Cmotif) ligand7  CCL7  Chemokine  9.241 
V-maf musculoaponeurotic fibrosarcoma oncogene homolog F  MAFF  Transcription factor & regulator  10.069 
GTP binding protein overexpressed in skeletal muscle  GEM  Signal Transduction  17.020 
Nuclear receptor subfamily 4, group A, member2  NR4A2  Signal Transduction  13.046 
Interleukin10 receptor, alpha  IL-10RA  Anti-inflammatory cytokine receptor  -2.713 
Interleukin10 receptor, beta  IL-10RB  Anti-inflammatory cytokine receptor  -2.171 
Vascular endothelial growth factor A  VEGFA  Angiogenesis  3.860 
Tumor necrosis factor superfamily member 14  TNFSF14  cytokine  7.698 
Interleukin 15  IL 15  cytokine  3.174 
 
Table 4: Differentially regulated pro-inflammatory gene signatures observed in RA and OA datasets 
Enterez Gene name  Gene Symbol  Function  Fold Change (RA)  Fold Change (OA) 
Interleukin1 receptor antagonist  IL1RN  Cytokine receptor  4.230  -1.132 
Tumor necrosis factor superfamily member11  TNF-SF11  Cytokine  4.380  1.309 
Interleukin 15  IL15  Cytokine  3.223  1.793 
Interleukin 8  IL8  Chemokine  1.248  -2.554 
(C-X-C motif)ligand 12  CXCL12  Chemokine  3.153  4.809 
Chemokine (C-C motif) ligand5  CCL5  Chemokine  48.605  8.177 
Fc fragment of IgG,high affinity Ia receptor  FCGR1A  Immunoregulatory gene  6.247 3.165 
Fc fragment of IgG, low affinity IIIb  FCGR3A  Immunoregulatory gene   4.019 2.956 
Transcription Factor 7  TCF-7  Transcription factor  42.261  1.045 
Mitogen activated protein kinase 1  MAPK1  Kinase  2.578 1.820 
Matrix Metalloprotenaise 3  MMP3  Enzyme  43.766 31.002 
Matrix Metalloprotenaise 1  MMP1  Enzyme  62.092 23.224 
Phospholipase C gamma 2  PLCG2  Enzyme  2.143  1.464 
Phospholipase C beta 1  PLCB1  Enzyme  -2.613  2.455 
Protein Kinase C beta  PRKCB  Kinase  7.294  -1.003 
Ras related C3 botulin toxin substrate 2  RAC2  Enzyme  14.468 5.668 
Vascular endothelial growth factor  VEGFC  Angiogenic growth factor  3.251 5.532 
T-cell receptor alpha locus  TCRα Receptor  23.112  2.644 
Chemokine (C-C motif) receptor5  CCR5  Chemokine receptor  7.396  1.139 
 
 
 
 
 
 